Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide) produce 15–25% mean weight loss and reduce cardiovascular events by 20% and type 2 diabetes incidence by 72%.
If you have obesity or overweight with a related health condition, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Zepbound) are currently the most effective pharmacological treatments, offering 15-25% weight loss and significant cardiovascular benefits. These require weekly injections (or oral forms for some) and work best when combined with a modest caloric deficit and regular exercise. Be aware of potential gastrointestinal side effects and the need for long-term management, as stopping the medication often leads to weight regain.
These agents demonstrate unprecedented efficacy, achieving 15–25% mean weight loss in clinical trials, alongside reducing major adverse cardiovascular events by 20% and T2D incidence by 72%.
Why this rating
Based on multiple phase 1-3 clinical trials (STEP, SURMOUNT) cited in the review.
Source
Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies
Mohammad I. Ullah et al. · Medicines · 2025
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →